New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith
  
close up of doctor giving subcutaneous injection.
Medicare is considering changing how it addresses certain combination products for price negotiation purposes, which could impact new subcutaneous cancer drug formulations. (Shutterstock)

More from Medicare

More from Pricing Debate